IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF
Innate Pharma SA
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$1.46+0.03 (+2.10%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
0M
Shares held, 13F filers
Institutional holders
10
3 new, 2 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Sanofi | 8,345,387 | 9.05% | 13G (passive) amendment | Apr 23, 2025 |
| AstraZeneca PLC | 7,825,501 | 8.30% | 13D (active) amendment | Dec 22, 2025 |
| Caisse des depots et consignations | 7,319,429 | 7.90% | 13D (active) amendment | Apr 25, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IPHA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Lion Point Capital, LP | 81,151 | – | $149.32K | – | 0.71% |
| Morgan Stanley | 43,524 | – | $80.08K | – | 0.00% |
| SmartHarvest Portfolios, LLC | 23,750 | – | $43.70K | New | 0.01% |
| XTX Topco Ltd | 15,130 | – | $27.84K | New | 0.00% |
| Citadel Advisors LLC | 12,441 | – | $22.89K | New | 0.00% |
| Jane Street Group, LLC | 10,310 | – | $18.97K | −33,055 | 0.00% |
| Rhumbline Advisers | 4,719 | – | $8.68K | −15 | 0.00% |
| UBS Group AG | 1,363 | – | $2.51K | +502 | 0.00% |
| Farther Finance Advisors, LLC | 21 | – | $38 | +11 | 0.00% |
| GAMMA Investing LLC | 9 | – | $17 | −231 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 10 | 0M | 3 / 2 | 3 / 2 | 0M | 0M |
| Q1 2026 | 9 | 0M | 1 / 0 | 6 / 3 | 0M | 0M |
| Q4 2025 | 11 | 0M | 5 / 1 | 4 / 3 | 0M | 0M |
| Q3 2025 | 9 | 0M | 1 / 1 | 3 / 1 | 0M | 0M |
| Q2 2025 | 9 | 0M | 1 / 3 | 3 / 2 | 0M | 0M |
| Q1 2025 | 10 | 0M | 3 / 2 | 1 / 2 | 0M | 0M |
| Q4 2024 | 9 | 0M | 1 / 1 | 3 / 0 | 0M | 0M |
| Q3 2024 | 8 | 0M | 0 / 1 | 4 / 0 | 0M | 0M |
| Q2 2024 | 8 | 0M | 1 / 2 | 2 / 2 | 0M | 0M |
| Q1 2024 | 9 | 0M | 1 / 4 | 1 / 0 | 0M | 0M |
| Q4 2023 | 8 | 0M | 0 / 2 | 3 / 0 | 0M | 0M |
| Q3 2023 | 8 | 0M | 0 / 1 | 3 / 1 | 0M | 0M |